Search results
Planet Fitness upgraded, Comcast downgraded: Wall Street's top analyst calls
The Fly via Yahoo Finance· 3 hours agoSiriusXM (LSXMA) has closed, the analyst tells investors in a research note. Citi upgraded Carrier...
Zealand Pharma soars after positive trial results from weight loss drug
Investing.com via Yahoo Finance· 3 days agoPetrelintide was “judged to be safe and well tolerated at all dose levels,” and the results provided “robust support” for its potential as an alternative to GLP-1 receptor agonist-based therapies ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $555.00 at Wells Fargo & Company
ETF DAILY NEWS· 7 hours agoThe firm currently has an “overweight” rating on the pharmaceutical company’s stock. Wells Fargo & Company‘s price objective suggests a potential upside of 18.41% from the ...
Intra-Cellular Therapies (NASDAQ:ITCI) PT Raised to $94.00 at Needham & Company LLC
ETF DAILY NEWS· 5 days agoThe brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Several other research firms have also issued reports on ITCI. Bank of America increased their target < ...
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
Investor's Business Daily· 55 minutes ago"We are highly encouraged by the large commercial opportunity in CIDP." Tazeen reiterated Argenx...
Taysha Gene Therapies (NASDAQ:TSHA) Given Overweight Rating at Cantor Fitzgerald
ETF DAILY NEWS· 4 days agoCantor Fitzgerald’s target price suggests a potential upside of 135.69% from the company’s current price. JMP Securities restated a “market outperform” ...
The latest trendy skin care treatment replacing the viral ‘vampire facial’
NY Post via Yahoo News· 7 days agoThe Kim Kardashian-endorsed platelet rich plasma procedure, or PRP, is being replaced at New York...
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
North Dakota Monitor via Yahoo News· 1 day agoAs a teenager growing up in northeastern Pennsylvania, she saw numerous neurologists and tried a...
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain...
Benzinga via AOL· 2 hours agoFriday, the FDA granted accelerated approval to Bristol Myers Squibb & Co’s (NYSE:BMY) Krazati...
Sarepta Therapeutics (NASDAQ:SRPT) Sees Strong Trading Volume After Analyst Upgrade
ETF DAILY NEWS· 5 hours agoRoyal Bank of Canada increased their target price on Sarepta Therapeutics from $142.00 to $182.00 and gave the stock a “sector perform” rating in a research report on Friday ...